Table 1.

Patient Information, CTC Counts, Tumor Staging, CTC and Biopsy Mutational Status, and Treatment Status of Colorectal Cancer Patients in the Study.

Patient	Age/Sex	CTC Count	Tumor Stage	CTC KRAS Status	Biopsy KRAS Status/Method	Treatment	Disease State	Total Cell Count	Time from Biopsy to CTC Collection (Days)
1	61/F	16	I	G12D	Not tested/N/A	N/A	N/A	2050	N/A
2	64/M	17	IV	Wild type	Wild type/PCR	Avas & Fol/Ava, 5-FU, Leu/Cli	Stable	1659	2120
3	49/F	93	II	Wild type	Wild type/Sanger	None	N/A	12,911	1
4	54/M	600	IV	Wild type	Wild type/PCR	Lav, 5-FU/FOL/Fol, Erb/Cli/FOL	Progressive	7314	699
5	58/F	7	IV	G13D	Wild type/Sanger	FOL	N/A	1129	148
6	71/M	71	IV	G12D, G12A	G12C/PCR	5-FU	N/A	3462	1098
7	73/M	23	IIIB	G13D	Wild type/Sanger	FOL/5-FU, Leu/Fol/FOL/5-FU, Eu/Cli/5-FU	Progressive (expired)	1389	69
8	59/M	0	IV	Wild type	Wild type/Sanger	FOL, Ava/Fol, Erb/Cli	Stable	1148	994
9	67/M	18	IV	Wild type	Wild type/Sanger	Oxa/Cli	N/A	5040	337
10	62/M	83	II	G13D	Wild type/Sanger	5-FU	N/A	2484	74
11	69/M	27	II	Wild type	Wild type/Sanger	5-FU	N/A	2213	1076
12	26/F	56	IV	Wild type	G13D/Sanger	FOL, bev/Fol, bev	Progressive	1729	223
13	63/M	82	III	G13D	Wild type/Sanger	FOL/Fol/5-FU, Leu/Fol, Ava/FOL, Ava	Progressive	887	414
14	64/M	0	IV	Wild type	Wild type/Sanger	5-FU, radiation/FOL/FOL, Ava	Partial response	924	670
15	75/M	18	IIB	G13D	Wild type/PCR	None	N/A	1098	1

Treatments administered: Folfiri (Fol), FOLFOX (FOL), 5-FU, Avastin (Ava), Leucovorin (Leu), bevacizumab (bev), Erbitux (Erb), cetixumab (cet), or clinical trial participation (Cli).